DE60143858D1 - Reduzierung DES RISIKOS FÜR KOMPLIKATIONEN BEI FRÜHGEBURTEN - Google Patents

Reduzierung DES RISIKOS FÜR KOMPLIKATIONEN BEI FRÜHGEBURTEN

Info

Publication number
DE60143858D1
DE60143858D1 DE60143858T DE60143858T DE60143858D1 DE 60143858 D1 DE60143858 D1 DE 60143858D1 DE 60143858 T DE60143858 T DE 60143858T DE 60143858 T DE60143858 T DE 60143858T DE 60143858 D1 DE60143858 D1 DE 60143858D1
Authority
DE
Germany
Prior art keywords
igf
binding protein
patient
risk
complications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60143858T
Other languages
German (de)
English (en)
Inventor
Lois Smith
Ann Hellstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Premacure AB
Original Assignee
Premacure AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0004405A external-priority patent/SE0004405D0/xx
Application filed by Premacure AB filed Critical Premacure AB
Application granted granted Critical
Publication of DE60143858D1 publication Critical patent/DE60143858D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
DE60143858T 2000-11-28 2001-11-13 Reduzierung DES RISIKOS FÜR KOMPLIKATIONEN BEI FRÜHGEBURTEN Expired - Lifetime DE60143858D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0004405A SE0004405D0 (sv) 2000-11-28 2000-11-28 New composition and use
US27425201P 2001-03-09 2001-03-09
PCT/US2001/047285 WO2002043578A2 (en) 2000-11-28 2001-11-13 Determination of risk and treatment of complications of prematurity

Publications (1)

Publication Number Publication Date
DE60143858D1 true DE60143858D1 (de) 2011-02-24

Family

ID=26655321

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60143858T Expired - Lifetime DE60143858D1 (de) 2000-11-28 2001-11-13 Reduzierung DES RISIKOS FÜR KOMPLIKATIONEN BEI FRÜHGEBURTEN

Country Status (9)

Country Link
US (2) US7144707B2 (cg-RX-API-DMAC10.html)
EP (1) EP1402266B1 (cg-RX-API-DMAC10.html)
JP (2) JP4173732B2 (cg-RX-API-DMAC10.html)
AT (1) ATE495443T1 (cg-RX-API-DMAC10.html)
AU (2) AU2002239560B2 (cg-RX-API-DMAC10.html)
CA (1) CA2429615C (cg-RX-API-DMAC10.html)
CY (1) CY1111213T1 (cg-RX-API-DMAC10.html)
DE (1) DE60143858D1 (cg-RX-API-DMAC10.html)
WO (1) WO2002043578A2 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1561228A (zh) * 2001-07-27 2005-01-05 哈特穆特M·汉瑙斯克－阿贝尔 增强新生儿的器官成熟度并预测重症监护时间
CN101553254A (zh) * 2006-10-03 2009-10-07 建新公司 TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途
WO2008130315A1 (en) 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
RU2338193C1 (ru) * 2007-07-18 2008-11-10 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ прогнозирования развития ретинопатии недоношенных
MX2010002562A (es) 2007-09-07 2011-04-11 Inst Nac De Ciencias Medicas Y Nutricion Uso de los niveles de antigeno secretor, de lewis y de sialilo como predictores para enfermedad.
AU2008325142A1 (en) * 2007-11-07 2009-05-14 Anthrogenesis Corporation Use of umbilical cord blood in the treatment of premature birth complications
JP5398054B2 (ja) * 2008-08-20 2014-01-29 株式会社 資生堂 「シミ」の蓋然性の評価方法
JP2012532195A (ja) 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
RU2445945C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2445946C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2445944C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
RU2445943C1 (ru) * 2010-10-14 2012-03-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ фотодинамической терапии задней агрессивной ретинопатии недоношенных
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
RU2526827C1 (ru) * 2013-05-23 2014-08-27 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации Способ прогнозирования развития пороговой стадии ретинопатии недоношенных у детей без офтальмологических признаков заболевания
JP5559406B2 (ja) * 2013-09-11 2014-07-23 株式会社 資生堂 シミを有する蓋然性を評価する方法
RU2536284C1 (ru) * 2013-09-19 2014-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Министерства здравоохранения Российской Федерации" (ГБОУ ВПО РНИМУ Минздрава России) Способ оценки тяжести течения и возможного исхода ретинопатии у недоношенных детей
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
RU2724013C2 (ru) * 2015-06-19 2020-06-18 Сера Прогностикс, Инк. Пары биологических маркеров для предсказания преждевременных родов
RU2639134C2 (ru) * 2016-01-21 2017-12-19 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Способ прогнозирования развития внутрижелудочковых кровоизлияний у новорожденных, родившихся после экстракорпорального оплодотворения
EP3681602B1 (en) * 2017-09-11 2026-04-15 Oak Hill Bio Limited Compositions for reducing the incidence of bpd
RU2741727C1 (ru) * 2020-07-06 2021-01-28 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Способ прогнозирования развития внутрижелудочковых кровоизлияний у недоношенных новорожденных
RU2741722C1 (ru) * 2020-07-06 2021-01-28 Федеральное государственное бюджетное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения Российской Федерации Способ прогнозирования внутрижелудочковых кровоизлияний у недоношенных новорожденных
EP3936054A1 (en) * 2020-07-08 2022-01-12 Assistance Publique - Hôpitaux de Paris Method of prognosis of bronchopulmonary dysplasia in premature infants
CN113528688A (zh) * 2021-09-09 2021-10-22 北京泱深生物信息技术有限公司 微生物在制备用于诊断生长发育迟缓的产品中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2033176C (en) * 1989-06-09 1999-12-14 Julian Richard Este Wells Growth hormone fusion proteins
SE9002731D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product comprising growth factor
EP0956041A1 (en) * 1996-09-16 1999-11-17 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CN1561228A (zh) 2001-07-27 2005-01-05 哈特穆特M·汉瑙斯克－阿贝尔 增强新生儿的器官成熟度并预测重症监护时间

Also Published As

Publication number Publication date
ATE495443T1 (de) 2011-01-15
EP1402266A4 (en) 2007-12-12
AU3956002A (en) 2002-06-11
US20070196857A1 (en) 2007-08-23
JP2008163043A (ja) 2008-07-17
US7144707B2 (en) 2006-12-05
JP5089443B2 (ja) 2012-12-05
CA2429615C (en) 2016-07-12
CY1111213T1 (el) 2015-06-11
JP2004528529A (ja) 2004-09-16
WO2002043578A3 (en) 2003-12-31
US20040053838A1 (en) 2004-03-18
EP1402266A2 (en) 2004-03-31
AU2002239560B2 (en) 2006-03-02
JP4173732B2 (ja) 2008-10-29
US7776820B2 (en) 2010-08-17
EP1402266B1 (en) 2011-01-12
WO2002043578A2 (en) 2002-06-06
CA2429615A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
CY1111213T1 (el) Ελαττωση του κινδυνου επιπλοκων πρωιμοτητας
Wallace et al. Pregnancy-specific protein B and progesterone concentrations in relation to nutritional regimen, placental mass and pregnancy outcome in growing adolescent ewes carrying singleton fetuses
Bökenkamp et al. Fetal serum concentrations of cystatin C and β2-microglobulin as predictors of postnatal kidney function
Austin et al. Pregnancy-specific protein B induces release of an alpha chemokine in bovine endometrium
Rey et al. The effects of first-trimester diabetes control on the incidence of macrosomia
Williams et al. Transient hypothyroxinemia in preterm infants: the role of cord sera thyroid hormone levels adjusted for prenatal and intrapartum factors
Yamada et al. Genetic factors in fetal growth restriction and miscarriage
POUTA et al. Midtrimester N-terminal proatrial natriuretic peptide, free beta hCG, and alpha-fetoprotein in predicting preeclampsia
Banik et al. Thyroid dysfunction in preeclampsia and related fetomaternal outcomes
Al Ghazali et al. Study of the clinical significance of serum albumin level in preeclampsia and in the detection of its severity
Öney et al. The value of the mean arterial blood pressure in the second trimester (MAP-2 value) as a predictor of pregnancy-induced hypertension and preeclampsia. A preliminary report
Lindqvist et al. Epidermal growth factor in maternal urine—a predictor of intrauterine growth restriction?
Briana et al. Perinatal bone turnover in term pregnancies: the influence of intrauterine growth restriction
Goel et al. Serial serum ferritin estimation in pregnant women at risk of preterm labor
Tjoa et al. Plasma hepatocyte growth factor as a marker for small-for-gestational age fetuses
Weems et al. PGE2 induces its own secretion in vitro by bovine 270-day placenta but not by 200-day placenta
Rehema et al. Ferrous iron administration during pregnancy and adaptational oxidative stress (Pilot study)
Taghavi et al. Outcome of thyroid dysfunction in pregnancy in Mashhad, Iran
Setia et al. Increased insulin sensitivity in intrauterine growth retarded newborns–do thyroid hormones play a role?
Xu et al. Maternal menstrual history and small-for-gestational-age births in a population-based Chinese birth cohort
Senses et al. Is there a relationship between cord blood pregnancy-associated plasma protein-A and birth weight and length?
Hsu et al. Maternal serum screening for Down syndrome in pregnancies conceived by intra‐uterine insemination
Pellicer et al. Prenatal brain damage in preeclamptic animal model induced by gestational nitric oxide synthase inhibition
Bindal et al. Role of maternal serum ferritin as a predictive marker in intrauterine growth restriction
Panigrahi et al. Prevalence of Antiphospholipid Antibodies in Patients with Bad Obstetric History of unknown Etiology and Its Association with Clinical Parameters